LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 4 registered trials.

Why this status

  1. 30 Dec 2020: Trial registered, NCT04689828
  2. 22 Jan 2021: Trial registered, NCT04720157
  3. 9 Jun 2021: Trial started, NCT04720157
  4. 15 Jun 2021: Trial started, NCT04689828

The trials

NCT04663997: 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

State
Under way
Phase
Phase 2
People
200 taking part
Started
11 Aug 2021
Primary completion
25 Aug 2025
Arms
177 Lu-PSMA-617
Results
None posted
  1. 11 Dec 2020: Trial registered
  2. 11 Aug 2021: Trial started

NCT04689828: 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

State
Completed
Phase
Phase 3
People
469 taking part
Started
15 Jun 2021
Primary completion
2 Oct 2022
Arms
177Lu-PSMA-617
Results
Posted on the registry
Papers
doi:10.1016/j.annonc.2025.07.003, doi:10.1016/s0140-6736(24)01653-2, doi:10.1016/s1470-2045(25)00189-5
  1. 30 Dec 2020: Trial registered
  2. 15 Jun 2021: Trial started
  3. 9 Oct 2025: Trial results posted
  4. 9 Sep 2026: Trial completed

NCT04720157: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

State
Under way
Phase
Phase 3
People
1,144 taking part
Started
9 Jun 2021
Primary completion
13 Jan 2025
Arms
177Lu-PSMA-617 + SoC
Results
Posted on the registry
Papers
doi:10.1016/s0140-6736(26)01092-5
  1. 22 Jan 2021: Trial registered
  2. 9 Jun 2021: Trial started
  3. 4 Nov 2026: Trial results posted

NCT05896371: A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy

State
Not started
Phase
Phase 1 and Phase 2
People
500 planned
Started
Mar 2028
Primary completion
Mar 2033
Arms
Cohort A, Cohort B, Cohort C, Cohort D, Cohort E
Results
None posted
  1. 9 Jun 2023: Trial registered

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Lutetium Lu 177 Vipivotide Tetraxetan, Pluvicto, [177Lu]Lu-PSMA-617.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.